DaVita Inc. ($DVA) Stock Forecast: Up 20.2% Today

What is DaVita Inc.?

DaVita Inc. is a kidney-care provider that posted strong Q4 2025 results, surpassing revenue and EPS estimates. The company also revised its 2026 outlook, resulting in a notable upsurge in its stock price.

Why is DaVita Inc. going up?

DVA stock is up 20.2% on Feb 3, 2026 18:46

• DaVita's robust Q4 performance and positive 2026 guidance bolstered investor confidence, leading to a 25% increase in its stock value.
• The 14.2% decline in short interest suggests a change in sentiment toward the company after its solid financial showing.
• Enhanced margins, driven by increased revenue per treatment and strategic acquisitions, contributed to the favorable market response and stock price appreciation.
• DaVita's commitment to enhancing patient care, reducing mortality rates, and pursuing future growth through strategic moves, as highlighted in the earnings call, further reinforced investor confidence in the company's future prospects.

DVA Price Chart

DVA Technical Analysis

DVA News

DaVita Inc Stock Soars 25% After DaVita Beats Q4 Results And Raises 2026 Outlook

DaVita Inc. (DVA) shares surged 24.57% after the kidney-care provider announced Q4 2025 results that exceeded expectations and provided strong 2026 guidance. The company reported $3.62 billion in Q4 revenue and adjusted EPS of $3.40, both beating Street estimates. This positive performance, coupled with optimistic 2026 adjusted earnings outlook, reinforced investor confidence and led to a significant breakout move in its stock.

https://www.nasdaq.com/articles/davita-inc-stock-soars-25-after-davita-beats-q4-results-and-raises-2026-outlook

Short Interest in DaVita Inc. (NYSE:DVA) Decreases By 14.2%

Short interest in DaVita Inc. (NYSE:DVA) decreased by 14.2% in January to 6,943,051 shares. The company reported strong Q4 results, beating EPS and revenue estimates, and raised its FY-2026 guidance, leading to a positive after-hours market reaction. However, concerns remain regarding declining net income and cash, rising liabilities, and mixed institutional and analyst sentiment.

https://www.marketbeat.com/instant-alerts/short-interest-in-davita-inc-nysedva-decreases-by-142-2026-02-03/

DaVita Stock Up Following Q4 Earnings & Revenue Beat, Margins Expand

DaVita (DVA) reported strong fourth-quarter and full-year 2025 results, with adjusted EPS up 51.8% year-over-year and revenues increasing 9.9%, both beating analyst estimates. The company saw an expansion in gross and operating margins, driven by higher revenue per treatment and strategic acquisitions, leading to an 11.8% increase in its stock in pre-market trading. Despite a slight sequential decrease in U.S. dialysis treatments, DaVita initiated a positive outlook for 2026, projecting continued growth in RPT and EPS.

https://www.tradingview.com/news/zacks:0cc8adde1094b:0-davita-stock-up-following-q4-earnings-revenue-beat-margins-expand/

DaVita Stock Up Following Q4 Earnings & Revenue Beat, Margins Expand

DaVita Inc. (DVA) reported strong fourth-quarter 2025 results, with adjusted earnings per share and revenues surpassing Zacks Consensus Estimates. The company saw a significant increase in adjusted EPS and revenue growth driven by higher revenue per treatment and an expanded gross margin. DaVita also provided an upbeat outlook for 2026, projecting continued growth in revenue per treatment and adjusted EPS.

https://sg.finance.yahoo.com/news/davita-stock-following-q4-earnings-152300537.html

DaVita Inc. (NYSE:DVA) Q4 2025 Earnings Call Transcript

DaVita Inc. reported its Q4 2025 earnings, beating expectations with an EPS of $3.40 against an anticipated $3.24. The company highlighted the profitability of its Integrated Kidney Care (IKC) programs ahead of schedule and discussed strategic initiatives to improve patient care, reduce mortality, and drive future volume growth. DaVita provided optimistic guidance for 2026, projecting adjusted operating income between $2.085 billion and $2.235 billion and adjusted EPS of $13.60 to $15.00, reflecting strong operating performance and capital allocation strategies.

https://www.insidermonkey.com/blog/davita-inc-nysedva-q4-2025-earnings-call-transcript-1687921/

Trending Today

Jupiter ($JUP) Crypto Forecast: Down 5.1% Today

Silver ($XAG) Commodity Forecast: Up 5.1% Today

Solana ($SOL) Crypto Forecast: Down 6.0% Today

Cosmos ($ATOM) Crypto Forecast: Up 5.1% Today

Gold ($XAU) Commodity Forecast: Up 5.1% Today

Ethereum ($ETH) Crypto Forecast: Down 5.2% Today

Revvity ($RVTY) Stock Forecast: Down 5.3% Today

Akamai Technologies Inc. ($AKAM) Stock Forecast: Down 5.1% Today

Avis Budget Group Inc. ($CAR) Stock Forecast: Up 5.1% Today

NXP Semiconductors N.V. ($NXPI) Stock Forecast: Down 6.1% Today

DaVita Inc. Price History

09.00.2026 - DVA Stock was down 1.8%

• DaVita HealthCare Partners stock hit a 52-week low at $112.53, reflecting a significant 24.81% decline over the past year.
• Despite trading below its Fair Value and having a strong free cash flow yield, the stock has been under pressure due to missing Q3 2025 earnings expectations, reporting an EPS of $2.51 against a projected $3.23.
• The company's aggressive share buyback program and the addition of a new board member, Gregory J. Moore, from Tolion Health AI, might indicate strategic efforts to navigate through the challenging market conditions.
• The extension of the Updated Product Purchase Agreement with Rockwell Medical with a price increase could potentially provide a slight boost to DaVita's revenue stream, but the overall market sentiment remains bearish for now.

30.09.2025 - DVA Stock was down 5.2%

• DaVita HealthCare (DVA) reported Q3 earnings below estimates, showing a negative surprise in earnings but a slight positive surprise in revenue.
• Despite efforts to enhance performance through technology upgrades and cost control, challenges like high missed treatments and low volume growth may have negatively impacted the stock.
• Investor concerns about the company's ability to address these operational issues and achieve sustainable growth may have contributed to today's bearish stock movement.

14.00.2026 - DVA Stock was down 5.8%

• On January 13, DaVita Inc. (DVA) experienced a notable decline of 3.83%, reaching an intraday low. Several factors could have contributed to this movement:
• The stock performed poorly compared to its industry peers, marking its third consecutive day of losses as major market indices like the S&P 500 and Dow Jones Industrial Average also saw declines.
• DaVita's stock reached a 52-week low, signaling a 33.52% drop over the past year. Despite analysts deeming it undervalued, the recent earnings disappointments and industry headwinds have fueled negative market sentiment.
• Analysts hold a bullish long-term perspective, setting price targets as high as $186. However, current market dynamics may be swayed by concerns surrounding financial performance and broader sectoral challenges.

13.00.2026 - DVA Stock was down 5.0%

• DaVita's stock plummeted to a 52-week low, reflecting a negative investor sentiment.
• Despite analysts deeming the stock undervalued and displaying strong financial indicators like a low P/E ratio and high free cash flow yield, a recent earnings disappointment likely contributed to the decline in stock value.
• The renewal of the supply agreement with Rockwell Medical, coupled with a price hike, could have sparked worries about DaVita's cost efficiency and future profitability, affecting investor trust.
• DaVita's shift towards a comprehensive kidney care platform, while holding potential long-term benefits, may be clouded by uncertainties over its implementation and short-term financial consequences, further fueling the negative market sentiment.

31.09.2025 - DVA Stock was down 6.2%

• Post its Q3 earnings release, DaVita's stock witnessed a downward trend.
• The company showed revenue growth, but its earnings fell short of expectations, resulting in a decline in stock prices.
• Concerns about financial performance arise from narrower margins and earnings below estimates.
• Investors seemed dissatisfied with the earnings miss, overshadowing positive elements such as revenue growth and cost management endeavors.

06.07.2025 - DVA Stock was down 7.8%

• Despite strong second-quarter 2025 results, including surpassing earnings and revenue expectations and a rise in gross margin from core operations, DaVita HealthCare (DVA) faced significant bearish movement.
• There may be concerns about future growth, particularly related to uncertainties surrounding PD supply issues that could affect the company's performance.
• Investors might have anticipated even better outcomes or guidance for the future, which led to profit-taking and a decrease in the stock price despite positive financial results.
• The decline in DaVita's stock price could also be influenced by general market trends and challenges specific to the healthcare sector, resulting in a larger drop for DaVita compared to the overall market.

10.11.2025 - DVA Stock was up 2.2%

• Despite DaVita Inc. falling short of recent EPS expectations and receiving cautious ratings from analysts, various institutional investors have notably increased their stakes in the company, including L2 Asset Management LLC, Norges Bank, Arrowstreet Capital Limited Partnership, Quantbot Technologies LP, and Edgestream Partners L.P.
• The stock's positive movement could be attributed to these institutional investments, indicating confidence in DaVita's long-term prospects despite recent performance challenges.
• Market attention appears to be shifting towards DaVita's future potential, as demonstrated by increased institutional ownership, rather than solely focusing on recent financial results and analyst outlooks.
• Anticipation surrounding the company's FY2025 guidance, which analysts are predicting DaVita will meet, may have also fueled positive sentiment and stock movement.

03.01.2026 - DVA Stock was up 23.2%

• DaVita delivered impressive Q4 2025 earnings, exceeding projections with an EPS of $3.40 and offering a positive outlook for 2026. This robust financial performance likely influenced the stock's upward trajectory.
• Institutional investors, such as Mirae Asset Global Investments Co. Ltd., notably enlarged their position in DaVita, demonstrating their faith in the company's future prospects.
• While concerns exist regarding slowing revenue growth and decreasing margins, DaVita's targeted efforts to enhance patient care and profitability appear to have garnered favor among investors, propelling the stock upwards.
• The prevailing positive sentiment in the market, as evidenced by the increase in S&P 500 futures, may have also contributed to the further rise in DaVita's stock value.

03.01.2026 - DVA Stock was up 20.2%

• DaVita's robust Q4 performance and positive 2026 guidance bolstered investor confidence, leading to a 25% increase in its stock value.
• The 14.2% decline in short interest suggests a change in sentiment toward the company after its solid financial showing.
• Enhanced margins, driven by increased revenue per treatment and strategic acquisitions, contributed to the favorable market response and stock price appreciation.
• DaVita's commitment to enhancing patient care, reducing mortality rates, and pursuing future growth through strategic moves, as highlighted in the earnings call, further reinforced investor confidence in the company's future prospects.

06.00.2026 - DVA Stock was down 2.5%

• The bearish movement in DaVita's stock today can be attributed to a cautious outlook.
• The extension of the supply agreement with Rockwell Medical, coupled with a price adjustment for products, might have raised concerns among investors about potential cost implications for DaVita.
• Despite recent success in cost controls and market optimism, DaVita faces challenges from U.S. healthcare policies and reimbursement risks, which could have contributed to the negative market sentiment.
• The ownership structure of DaVita, with Berkshire Hathaway as a major shareholder reducing its stake, alongside insider trading activities indicating a cautious approach, may have added to the downward pressure on the stock.

07.00.2026 - DVA Stock was down 3.8%

• DaVita HealthCare Partners stock hit a 52-week low due to a 24.81% decline over the past year, exacerbated by a recent earnings miss in Q3 2025.
• Despite trading below its Fair Value and having a strong free cash flow yield, the company's challenges in the market and the earnings disappointment contributed to the bearish movement.
• The extension of the supply agreement with Rockwell Medical, including a price adjustment, may have also impacted investor sentiment, adding to the overall negative outlook for DaVita HealthCare Partners.
• The addition of a former Microsoft and Google executive to Tolion Health AI's Board could signal potential strategic shifts in the industry, but it did not provide enough positive momentum to offset the stock's downward trend.

29.09.2025 - DVA Stock was down 1.9%

• Despite potential benefits from technology upgrades and cost control, DVA experienced a strong bearish movement.
• The high number of missed treatments and low volume growth likely impacted DVA's performance negatively.
• Investors may have reacted to these challenges by selling off DVA shares, leading to the bearish market movement today.